Bibliography
- World Health Organization. Diabetes Mellitus. Facts sheet 2006, number 316. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/
- Centers for Disease Control and Prevention. Diabetes Mellitus Press Release. Number of People with Diabetes Increases to 24 Million. June 2008, Available from: http://www.cdc.gov/media/pressrel/2008/r080624.htm
- The Medical Letter on Drugs and Therapeutics. Insulin Glulisine (Apidra): a new rapid-acting insulin. 2006;48:33-4
- Guyton AC, Hall ME. Insulin, Glucagon, and Diabetes Mellitus. Tenth Edition. In: Textbook of Medical Physiology. Philadelphia; Saunders 2000. p. 884-98
- Sanofi-Aventis U.S. LLC. APIDRA® prescribing information. Bridgewater, NJ, USA, April 2007. Available from: http://products.sanofi-aventis.us/apidra/apidra.html
- Robinson D, Wellington K. Insulin glulisine. Drugs 2006;66:861-9
- Ulrich H, Snyder B, Garg S. Combining insulins for optimal blood glucose control in type 1 and type 2 diabetes: Focus on insulin glulisine. Vasc Health Risk Manag 2007;3(3):245-54
- Becker R, Frick A. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008;47(1):7-20
- Becker R, Frick A, Burger F, et al. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin Ednocrinol Diabetes 2005;113(5):292-7
- Becker R, Frick A, Nosek L, et al. Dose-response relationship of insulin glulisine in subjects with type 1 diabetes. Diabetes Care 2007;30(10):2506-7
- Becker R, Frick A, Wessels D. Pharmacodynamics and pharmacokinetics of a new, rapidly-acting insulin analog, insulin glulisine [abstract 471-P]. Diabetes 2003;52(Suppl 1):A110
- Rave K, Klein O, Frick A, Becker R. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care 2006;29(8):1812-7
- Becker R, Frick A, Kapitsa C, et al. Pharmacodynamics (PD) and pharmacokinetics (PK) of insulin glulisine compared with insulin lispro (IL) and regular human insulin (RHI) in patients with type 2 diabetes [abstract 503-P]. Diabetes 2004;53(Suppl 2):A119
- Burger F, Scholtz H, Frick A, et al. Pharmacodynamics (PD) and pharmacokinetics (PK) of insulin glulisine compared with insulin lispro (IL) and regular human insulin (RHI) in patients with type 1 diabetes [abstract 2350-PO]. 64th Annu Meet Sci Sess Am Diabetes Assoc (June 4 – 8, Orlando) 2004
- Becker R, Burger F, Scholtz H, et al. Bioefficiency of insulin glulisine versus regular human insulin [abstract 2340-PO]. 64th Annu Meet Sci Sess Am Diabetes Assoc (June 4 – 8, Orlando) 2004
- Frick A, Becker R, Wessels D, et al. Pharmacokinetic and glucodynamic profiles of insulin glulisine following subcutaneous administration at various injection sites [abstract 471-P]. Diabetes 2003;52(Suppl 1):A110
- Rave K, Nosek L, Heinmann L, et al. Insuline glulisine: pharmacokinetic and pharmacodynamic properties in comparison with insulin lispro and regular human insulin in Japanese and Caucasian volunteers [abstract 603-P]. Diabetes 2004;53(suppl 2):A143
- Danne T, Becker R, Heise T, et al. Pharmacokinetics, prandial glucose control, and safety of insuilin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005;28(9):2100-5
- Frick A, Burger F, Scholtz H, et al. Time action profile of insulin glulisine (GLU) versus regular human insulin (RHI) and insulin lispro (IL) in obese subjects [abstract 526-P]. Diabetes 2004;53(Suppl 2):A124
- Jaros M, Martinek V, Piechatzek R, et al. Pharmacokinetics of insuline glulisine in renally impaired patients without diabetes [abstract 1330-P]. Diabetes 2004;53(Suppl 2):A321
- Frick AD, Scholtz H, Burger F, et al. Absorption of insulin glulisine when mixed with NPH insulin [abstract 1329-P]. Diabetes 2004;539(Suppl2):A321
- Becker R. Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther 2007;9(1):109-21
- Horvath K, Bock G, Regittnig W, et al. Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study. Diabetes Obes Metab 2008;10:484-91
- Garg S, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract 2005;11:11-7
- Dreyer M, Prager R, Robinson A, et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 2005;37:702-7
- Dailey G, Rosenstock J, Moses R, et al. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004;27(10):2363-8
- Kamal A, Bain S. Insulin glulisine: efficacy and safety compared with other rapid-acting insulin analogues. Expert Opin Drug Saf 2007;6(1):5-7
- Stammberger I, Seipke G, Bartels T. Insuline glulisine – a comprehensive preclinical evaluation. Int J Toxicol 2006;25:25-33
- Clarke A, Spollet G. Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin Drug Deliv 2007;4(2):165-74
- Hoogma R, Schumicki D. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res 2006;38:429-33
- Poulsen C, Langkjær L, Worsøe C. Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion. Diabetes Technol Ther 2007;9(1):26-35